In 2019, Esketamine, a subtype of ketamine, in the form of a nasal spray (Spravato) was patented by Johnson & Johnson and was approved for the treatment of TRD with accompanying suicidal ideation by both the FDA and EMA. Spravato was developed through their Janssen Pharmaceuticals subsidiary.
The costs of Spravato are significantly higher than that of ketamine which has led the UK’s National Institute for Health and Care Excellence (NICE) to not approve it as a medicine. Nonetheless, Spravato is currently the only available psychedelic on the market.
B2B B2C Manufacturing Pharmaceutical Biotech Drug Discovery
Topics of Interest
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates